// App-Quantinova.ai

: Preclinical data using a novel porcupine inhibitor demonstrates that inhibition of porcupine is a promising target for the treatment of Idiopathic Pulmonary Fibrosis

Researchers

Presenter

  • Peter Bunyard

Principal Investigators

  • Inder Bhamra

  • Kay Eckersley

  • Claire Chaplin

  • Nicolas Guisot

  • Cliff Jones

  • Caroline Phillips

  • Richard Armer

Medical Centers

  • Redx Pharma Plc, Alderley Edge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Idiopathic pulmonary fibrosis

  • Kidney fibrosis

  • Hepatic fibrosis

Biomarkers

  • beta-catenin

  • Connective tissue growth factor

  • Smooth muscle alpha-actin

Drug/Treatment

  • Bleomycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved